Is this clean energy producer stock worth a buy right now: Gevo Inc. (NASDAQ:GEVO)?

Is this clean energy producer stock worth a buy right now: Gevo Inc. (NASDAQ:GEVO)?

ByMarketFacts

Gevo Inc. (XNAS: GEVO) is a renewable chemicals and biofuel company that develops and commercializes alternatives to petroleum-based goods based on isobutanol derived from renewable feedstocks. Its operational segments include the Gevo sector, the Renewable Natural Gas segment, the Net-Zero segment, and the Agri-Energy business. It is engaged in research and development efforts linked to the future production of isobutanol, including developing its biocatalysts, manufacturing and selling biojet fuel, and creating biocatalysts. Gevo Development/Agri-Energy is the most important revenue-generating business, consisting of the operation of the Luverne Facility and the manufacture of ethanol, isobutanol, and associated products. 

Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

ByMarketFacts

Y-mAbs Therapeutics Inc. (XNAS: YMAB), incorporated in 2015 and headquartered in New York is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform.

The Company’s broad and advanced product pipeline includes one FDA-approved product, DANYELZA, which targets tumors that express GD2, and one product candidate at the registration stage, OMBLASTYS, which targets tumors that express B7-H3.

The Ultimate Guide to Dividend Stocks

The Ultimate Guide to Dividend Stocks

ByMarketFacts

The stock of companies that pay out a portion of their earnings to a class of shareholders on a regular basis are known as Dividend Stocks. Dividend investing provides investors with steady cash flow over the long term. Most dividends are paid out on a quarterly basis, but some are paid out monthly, annually, or even once in the form of a special dividend.

Larger, established companies with predictable profits are often the best dividend payers and industry sectors such as Basic Materials, Oil & Gas, Banks & Financial, Health Care and Utilities maintain a regular record of dividend payments

Hitch a ride to the EV boom with Blink Charging Co. (NASDAQ:BLNK)

Hitch a ride to the EV boom with Blink Charging Co. (NASDAQ:BLNK)

ByMarketFacts

Blink Charging Co. (XNAS: BLNK) provides electric vehicle (EV) charging equipment and networked EV charging services in the United States and internationally. The Company was founded in 2009 and is headquartered in Miami Beach, Florida.

Blink offers residential and commercial EV charging equipment that enable EV drivers to recharge at various location types. The company offers its services through direct sales force and resellers, as well as sells residential Level 2 chargers through various internet channels.

Are Green Bonds good investment option for long term retail Investors?

Are Green Bonds good investment option for long term retail Investors?

ByMarketFacts

Green Bonds is a type of fixed income security issued to raise money for climate & environmental projects. Like any other type of bond, green bonds offer a stated return and represent a loan from an investor to a company, organization, or government agency.

Green bonds may come with tax incentives such as tax exemption and tax credits, making them a more attractive investment vs. a comparable taxable bond. Investors interested in green bonds should learn the diverse types and the pros and cons of investing before buying.

What Is Equity Research and Why Is It Important?

What Is Equity Research and Why Is It Important?

ByMarketFacts

There are many uncertainties surrounding the stock market, so investing in stocks has always been seen as a gamble. It is a common misconception in the stock market that success depends entirely on chance. A miracle may bring instant riches; a catastrophe may ruin all your hard work.

Everything is true to an extent, but equity research comes into play to protect people from the uncertainties of the stock market. Equity research acts as a timely and effective shield, ensuring the protection of investors.

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

ByMarketFacts

Douglas Elliman Inc. (XYNS: DOUG) is a real estate company. Among other real estate-related services, it provides sales, rentals, and new development in combination with mortgages and title insurance. The company operates in two divisions: Real Estate Brokerage and Corporate and Other. The company makes revenue from Commission and other brokerage income from existing house sales, Commission and other brokerage income from development marketing, Property management income, and Title fees. 

How to survive bear market ?

How to survive bear market ?

ByMarketFacts

As reflected in the Standard & Poor’s 500 and the Nasdaq Composite Index, a Bear Market is commonly defined as a stock market decline of 20% or more from its recent highs. Factors such as weak or declining economy, pandemics, wars, interest rate hikes, oil price movements, bursting market bubbles and unexpected high inflation figures can all contribute to a bear market.  

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

ByMarketFacts

Protagonist Therapeutics, Inc.(XNAS:PGTX) is a biopharmaceutical company that discovers and develops peptide based therapeutic drugs to address hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 antagonist peptide, which is currently in Phase II clinical trials for the treatment of inflammatory bowel disease (IBD); and PN-235, an interleukin-23 receptor antagonist for the treatment of both IBD and non-IBD indications. A license and collaboration agreement has been signed between the company and Janssen Biotech Inc.

Is this solar energy stock worthy enough to be in your portfolio: Sunrun Inc.(NASDAQ: RUN)?

Is this solar energy stock worthy enough to be in your portfolio: Sunrun Inc.(NASDAQ: RUN)?

ByMarketFacts

Sunrun Inc. (XNAS: RUN) is an American provider of photovoltaic solar energy generation systems and battery energy storage products, primarily for residential customers. The company was established in 2007 and is headquartered in San Francisco, California. Sunrun Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company markets and sells its products through direct-to-consumer approach across online, retail, mass media as well as its partner network. The company installs solar energy systems on its customers’ homes and provides them with the solar power produced by those systems for a 20- or 25-year initial term. It monitors, maintains, and ensures the system during the term of the contract.